Antitumor activity of novel octalactin A analogs in murine leukemia cells in vitro

Anticancer Research

Volumn 18, Issue 1 A, 1998, Pages 97-106

  Perchellet, Jean Pierre ^a,b   Perchellet, Elisabeth M ^a   Newell, Steven W ^a   Freeman, Jonathan A ^a   Ladesich, James B ^a   Jeong, Youngmee ^b   Sato, Nagaaki ^b   Buszek, Keith ^b  

^a Anti Cancer Drug Laboratory   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

L1210 cells; Macromolecule synthesis; Octalactin A; Tubulin polymerization; Tumor cell growth

Indexed keywords

'K1'; 'K3'; 'K4'; 'K5'; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CISPLATIN; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DNA; ETOPOSIDE; FLUOROURACIL; K6; K7; K8; K9; LACTONE; MERCAPTOPURINE; METHOTREXATE; OCTALACTIN A; PROTEIN; RNA; TUBULIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG MECHANISM; DRUG SYNTHESIS; LEUKEMIA CELL; LEUKEMIA L 1210; MICROTUBULE; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; PROTEIN SYNTHESIS; RNA SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL DIVISION; CELL SURVIVAL; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH INHIBITORS; LACTONES; LEUKEMIA L1210; MICE; MICROTUBULES; NEOPLASM PROTEINS; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 0031946263     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Tapiolas DM, Roman M, Fenical W, Stout TJ and Clardy J: Octalactins A and B: cytotoxic eight- membered-ring lactones from a marine bacterium, Streptomyces sp. J Am Chem Soc 113: 4682-4683, 1991.
2. Buszek KR, Sato N and Jeong Y: Total synthesis of octalactin A and B. J Am Chem Soc 116: 5511-5512, 1994.
3. Buszek KR and Jeong Y: An improved synthesis of the octalactins. Tetrahedron Lett 36: 7189-7192, 1995.
4. Perchellet JP, Perchellet EM, Newell SW, Freeman JA, Ladesich JB, Jeong Y, Sato N and Buszek KR: Antitumor activity of novel octalactin A analogs in vitro. IIAR Conf New Anticancer Agents, Kapandriti, Athens, Greece, Oct 12-15, 1997. Anticancer Res (in press): 1997.
5. Chabner BA and Myers CE: Clinical pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S and Rosenberg SA (eds.), Cancer Principles and Practice of Oncology. JB Lippincott, Philadelphia, pp. 287-328, 1985.
6. Erlichman C: The pharmacology of anticancer drugs. In: Tannock IF and Hill RP (eds.), The Basic Science of Oncology. Pergamon Press, New York, pp. 292-307, 1987.
7. Eisenbrand G, Habs M and Schmahl D: Pharmacology and toxicology of antineoplastic agents. In: Kuemmerle HP, Berkarda B, Karrer K and Mathe G (eds.), Clinical Chemotherapy, Vol. III, Antineoplastic Chemotherapy. Thieme-Stratton, New York, pp. 35-91, 1984.
8. Tanaka N: Mode of action of different substances. In Kuemmerle HP, Berkarda B, Karrer K and Mathe G (eds.), Clinical Chemotherapy, Vol. III, Antineoplastic Chemotherapy. Thieme-Stratton, New York, pp. 139-168, 1984.
9. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
10. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291, 1993.
11. Potmesil M: Camptothecins: from bench research to hospital wards. Cancer Res 54: 1431-1439, 1994.
12. Wall ME and Wani MC: Camptothecin and taxol: discovery to clinic. 13th Bruce F. Cain Memo'rial Award Lecture. Cancer Res 55: 753-760, 1995.
13. Furth JJ and Cohen SS: Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1-β-D-arabinofuranosylcytosine and the 5'-triphosphate of 9-β-D-arabinofuranosyladenine. Cancer Res 28: 2061-2067, 1968.
14. Schrecker AW: Metabolism of 1-Β-D-arabinofuranosylcytosine in leukemia L1210: nucleoside and nucleotide kinases in cell-free extracts. Cancer Res 30: 632-641, 1970.
15. Cohen SS: The lethality of ara nucleotides. Med. Biol 54: 299-326, 1976.
16. Chabner BA, Hande KR and Drake JC: Ara-C metabolism: implications for drug resistance and drug interactions. Bull. Cancer 66: 89-92, 1979.
17. Krakoff IH: Antimetabolites. In: Kuemmerle HP, Berkarda B, Karrer K and Mathe G (eds.), Clinical Chemotherapy, Vol. III, Antineoplastic Chemotherapy. Thieme-Stratton, New York, pp. 187-204, 1984.
18. Burghardt RC, Barhoumi R, Doolittle DJ and Phillips TD: Application of cellular fluorescence imaging for in vitro toxicology testing. In: Hayes AW (ed.), Principles and Methods of Toxicology. Raven Press, New York, pp. 1231-1258, 1994.
19. Engelborghs Y: Dynamic aspects of microtubule assembly. In: Avila J (ed.), Microtubule Proteins. CRC Press, Boca Raton, FL, pp. 1-35, 1990.
20. Rosenberg B: Fundamental studies with cisplatin. In: Kuemmerle HP, Berkarda B, Karrer K and Mathe G (eds.), Clinical Chemotherapy, Vol. III, Antineoplastic Chemotherapy. Thieme-Stratton, New York, pp. 245-263, 1984.
21. Roberts JJ: Molecular mechanisms of action of anti-tumor platinum compounds. In: Chagas C and Pullman B (eds.), Working Group on Molecular Mechanisms of Carcinogenic and Antitumor Activity. Pontifica Academia Scientiarum, Vatican City, Italy, pp. 463-489, 1987.
22. Jones J, Zhen W, Reed E, Parker RJ, Sancar A and Bohr VA: Genespecific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem 266: 7101-7107, 1991.
23. Schomagel JH and McVie JG: The clinical pharmacology of methotrexate. Cancer Treat Rev 10: 53-75, 1983.
24. Jukes TH: Searching for magic bullets: early approaches to chemotherapy_ Antifolates, methotrexate_ The Bruce F. Cain Memorial Award Lecture. Cancer Res 47: 5528-5536, 1987.
25. Myers CE: The pharmacology of the fluoropyrimidines. Pharmacol Rev 33: 1-15, 1981.
26. Bachur NR: Adriamycin-daunorubicin cellular pharmacodynamics. Biochem Pharmacol 23 (Suppl. 2): 207-216, 1974.
27. Drewinko B and Barlogie B: Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. Cancer Treat Rep 60: 1295-1306, 1976.
28. Wozniak AJ and Ross WE: DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-β-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res 43: 120-124, 1983.
29. D'Arpa P and Liu L: Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163-177, 1989.
30. Pommier Y: DNA topoisomerase I and II in cancer chemotherapy: update and perspective. Cancer Chemother Pharmacol 32: 103-108, 1993.
31. Owellen RJ, Owens AH and Donigian DW: The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun 47: 685-691, 1972.
32. Owellen RJ, Hartke CA, Dickerson RM and Hains FO: Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class. Cancer Res 36: 1499-1502, 1976.
33. Hamel E: Interaction of tubulin with small ligands. In: Avila J (ed.), Microtubule Proteins. CRC Press, Boca Raton, FL, pp. 89-191, 1990.
34. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280, 1990.
35. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11: 121-139, 1992.
36. da Silva CP, de Oliveira CR and da Conceição de Lima M: Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem Pharmacol 51: 1331-1340, 1996.
37. Martin DS and Schwartz GK: Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade. Oncology Res 9: 1-5, 1997.